REGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

616.240

Open

612.070

VWAP

608.12

Vol

2.61M

Mkt Cap

63.95B

Low

598.190

Amount

1.59B

EV/EBITDA(TTM)

12.66

Total Shares

104.84M

EV

57.69B

EV/OCF(TTM)

11.51

P/S(TTM)

4.39

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

Show More

Events Timeline

(ET)

2026-06-15

13:00:00

RBC Analyst Says CMS to Make Drug Price Negotiation Permanent, Impacting J&J and Others

2026-06-03 (ET)

2026-06-03

08:10:00

CytomX Expands Collaboration Agreement with Regeneron

2026-05-28 (ET)

2026-05-28

16:10:00

Regeneron's Maftivimab Recommended by WHO for Ebola Clinical Trials

2026-05-22 (ET)

2026-05-22

07:10:00

Regeneron Announces EMA Accepts Otarmeni for Accelerated Review

2026-05-18 (ET)

2026-05-18

16:20:00

Stocks Open Mixed as Rising Oil Prices Raise Concerns

2026-05-18

12:10:00

U.S. Stocks Mostly Lower at Noon as Oil Prices Climb

2026-05-18

10:10:00

Regeneron Shares Drop 11.1% to $621.00

News

CNBC

Grand Opening of the Obama Presidential Center

Fool

Intellia Therapeutics Shows Significant Progress, Stock Up 58%

NASDAQ.COM

06-17NASDAQ.COM

Intellia Therapeutics' Drug Phase 3 Trial Success

CNBC

Trump Announces US-Iran Deal, Market Rallies

NASDAQ.COM

06-10NASDAQ.COM

Sensorion Selects SENS-601 as Lead Program for Hearing Loss Treatment

Globenewswire

06-09Globenewswire

Pomerantz LLP Investigates Regeneron for Securities Fraud

22 Analyst Rating

Wall Street analysts forecast REGN stock price to rise

16 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

637.00

Averages

808.50

High

1057

Current: 0.000

Low

637.00

Averages

808.50

High

1057

Canaccord

John Newman

Buy

downgrade

$875

AI Analysis

2026-05-19

Reason

Canaccord

John Newman

Price Target

$875

AI Analysis

2026-05-19

downgrade

Buy

Reason

Canaccord analyst John Newman lowered the firm's price target on Regeneron to $875 from $1,057 and keeps a Buy rating on the shares. The firm updated its model following its Phase 3 study of fianlimab+cemiplimab vs pembrolizumab failed to hit statistical significance on the primary endpoint of progression-free survival (PFS), a surprising and disappointing event.

Wolfe Research

Alexandria Hammond

Outperform

to

Outperform

downgrade

$900 -> $860

2026-05-18

Reason

Wolfe Research

Alexandria Hammond

Price Target

$900 -> $860

2026-05-18

downgrade

Outperform

to

Outperform

Reason

Wolfe Research analyst Alexandria Hammond lowered the firm's price target on Regeneron to $860 from $900 and keeps an Outperform rating on the shares. The company's LAG-3 trial missed its primary endpoint, and while the opdualag head-to-head trial may presented a path forward through the FDA, the firm is less optimistic, the analyst tells investors in a research note. Commercial execution will be important for Regeneron going forward, while 2H26 catalysts may be underappreciated, the firm adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN.O) is 13.70, compared to its 5-year average forward P/E of 16.74. For a more detailed relative valuation and DCF analysis to assess Regeneron Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

16.74

Current PE

13.70

Overvalued PE

19.88

Undervalued PE

13.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

11.82

Current EV/EBITDA

15.41

Overvalued EV/EBITDA

14.61

Undervalued EV/EBITDA

9.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

5.74

Current PS

3.67

Overvalued PS

6.88

Undervalued PS

4.61

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

then do u have other alternative stock

Intellectia · 8 candidates

Market Cap: >= 5.00BThemes: BiotechAnalyst Consensus: Moderate Buy, Strong BuyMoving Average Relationship: PriceAboveMA200Is Optionable: True

Ticker

Name

Market Cap$

Amgen Inc

181.47B

Gilead Sciences, Inc

160.88B

Vertex Pharmaceuticals Inc

110.90B

Regeneron Pharmaceuticals Inc

73.20B

Biogen Inc

28.49B

Incyte Corp

19.04B

find me the best stocks for free

Intellectia · 20 candidates

Net Margin: >= 10.00Revenue 5yr Cagr: >= 5Eps 5yr Cagr: >= 5Pe Ttm: 5 - 30P/B Ratio: <= 5.00Return On Equity: >= 12.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Goldman Sachs Group Inc

238.24B

Nextera Energy Inc

191.79B

Chubb Limited

127.24B

Newmont Corporation

111.36B

CME Group Inc

107.96B

PNC Financial Services Group Inc

81.34B

top stocks in health sector

Intellectia · 38 candidates

Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%

Ticker

Name

Market Cap$

Eli Lilly and Co

866.87B

AbbVie Inc

364.65B

AstraZeneca PLC

293.00B

Merck & Co Inc

282.35B

UnitedHealth Group Inc

254.55B

Amgen Inc

188.63B

what stock should I buy today

Intellectia · 52 candidates

Pe Ttm: 12 - 30Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Johnson & Johnson

573.51B

Micron Technology Inc

519.64B

Coca-Cola Co

333.92B

Cisco Systems Inc

313.11B

Merck & Co Inc

286.48B

Linde PLC

228.94B

how to use AI screener

Intellectia · 74 candidates

Market Cap: >= 10.00BRevenue 5yr Cagr: >= 8Pe Ttm: 10 - 25Return On Equity: >= 15.0%Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

JPMorgan Chase & Co

764.45B

Merck & Co Inc

285.83B

Morgan Stanley

245.91B

Royal Bank of Canada

225.22B

Novo Nordisk A/S

169.49B

Charles Schwab Corp

163.06B

what to buy or sell now

Intellectia · 39 candidates

Market Cap: >= 20.00BRevenue 5yr Cagr: >= 8Pe Ttm: 12 - 30Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX, DJI

Ticker

Name

Market Cap$

Exxon Mobil Corp

639.72B

Cummins Inc

74.44B

Halliburton Co

29.18B

Newmont Corporation

124.54B

Ameren Corp

30.41B

Regeneron Pharmaceuticals Inc

78.93B

give me a selection of long term stocks

Intellectia · 27 candidates

Market Cap: >= 50.00BRevenue 5yr Cagr: >= 8Pe Ttm: 12 - 30Return On Equity: >= 13.0%Is Index Component: GSPC

Ticker

Name

Market Cap$

Meta Platforms Inc

1.66T

JPMorgan Chase & Co

775.45B

Micron Technology Inc

471.24B

Merck & Co Inc

287.32B

Morgan Stanley

255.47B

Goldman Sachs Group Inc

244.45B

stock to buy today

Intellectia · 20 candidates

Market Cap: >= 50.00BNet Margin: >= 15.00Pe Ttm: 10 - 25Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

Anglogold Ashanti PLC

63.67B

Agnico Eagle Mines Ltd

123.28B

Canadian National Railway Co

67.41B

Newmont Corporation

138.67B

Novartis

315.82B

CSX Corp

79.31B

best stocks to buy

Intellectia · 28 candidates

Market Cap: >= 30.00BRegion: USRevenue 5yr Cagr: >= 10Pe Ttm: 12 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Meta Platforms Inc

1.62T

Micron Technology Inc

463.33B

American Express Co

231.73B

Novo Nordisk A/S

221.33B

Charles Schwab Corp

166.53B

ICICI Bank Ltd

109.25B

welche us Aktien soll ich heute kaufen?

Intellectia · 53 candidates

Market Cap: >= 0Revenue 5yr Cagr: >= 8Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

JPMorgan Chase & Co

813.77B

Micron Technology Inc

439.39B

Morgan Stanley

287.52B

Goldman Sachs Group Inc

277.15B

Merck & Co Inc

266.87B

American Express Co

247.25B

Whales Holding REGN

ARS Investment Partners, LLC

Wolverine Trading, LLC

ProFund Advisors LLC

Nearwater Capital Markets, Limited

Applied Finance Advisors, LLC

Point72 Asset Management, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc (REGN) stock price today?

The current price of REGN is 609.94 USD — it has increased 0.33

What is Regeneron Pharmaceuticals Inc (REGN)'s business?

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

What is the price predicton of REGN Stock?

Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regeneron Pharmaceuticals Inc (REGN)'s revenue for the last quarter?

Regeneron Pharmaceuticals Inc revenue for the last quarter amounts to 3.60B USD, increased 19.04

What is Regeneron Pharmaceuticals Inc (REGN)'s earnings per share (EPS) for the last quarter?

Regeneron Pharmaceuticals Inc. EPS for the last quarter amounts to 6.75 USD, decreased -7.15

How many employees does Regeneron Pharmaceuticals Inc (REGN). have?

Regeneron Pharmaceuticals Inc (REGN) has 15410 emplpoyees as of June 19 2026.

What is Regeneron Pharmaceuticals Inc (REGN) market cap?

Today REGN has the market capitalization of 63.95B USD.